Arix Bioscience (LON:ARIX) Receives “Buy” Rating from Stifel Nicolaus

Arix Bioscience (LON:ARIX)‘s stock had its “buy” rating reiterated by analysts at Stifel Nicolaus in a research note issued to investors on Thursday, April 11th, ThisIsMoney.Co.Uk reports.

Separately, Jefferies Financial Group restated a “buy” rating and set a GBX 288 ($3.76) target price on shares of Arix Bioscience in a report on Tuesday, February 19th.

LON:ARIX traded up GBX 1.50 ($0.02) during trading hours on Thursday, hitting GBX 156.50 ($2.04). 146,741 shares of the stock were exchanged, compared to its average volume of 65,433. The firm has a market cap of $195.60 million and a P/E ratio of 5.45. Arix Bioscience has a 52-week low of GBX 137 ($1.79) and a 52-week high of GBX 213 ($2.78).

About Arix Bioscience

Arix Bioscience plc, formerly known as Perceptive Bioscience Investments Limited, is a venture capital firm specializing in seed, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, medical innovation comprising healthcare and life sciences.

See Also: Investing strategies using the yield curve

Receive News & Ratings for Arix Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arix Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.